Sirna Therapeutics to Report Second Quarter 2006 Financial Results on August 14, 2006
August 07 2006 - 6:25PM
PR Newswire (US)
Conference Call to Be Held at 4:30 p.m. EDT SAN FRANCISCO, Aug. 7
/PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. ("Sirna")
(NASDAQ:RNAI), a leading RNAi-based therapeutics company, announced
today that it will release second quarter financial results for the
period ended June 30, 2006 after the close of the U.S. financial
markets on Monday, August 14, 2006. Howard W. Robin, Sirna
President and CEO, and the Sirna senior management team will
discuss progress to date in their clinical and preclinical programs
and provide an overview of financial results during a conference
call on Monday, August 14 at 4:30 p.m. EDT (1:30 p.m. PDT). A live
audio webcast of the call will be available at the Company's
corporate web site at http://www.sirna.com/. Participants are urged
to log on to the web site 15 minutes prior to the scheduled start
time to download and install any necessary audio software. To
access the live telephonic broadcast, domestic callers should dial
(877) 502-9273; international callers may dial (913) 981-5582. An
audio webcast replay will be available on Sirna's web site,
http://www.sirna.com/, for 30 days. Additionally, a telephonic
replay of the call will be maintained through midnight, Monday,
August 28, 2006. To access the replay, please dial (888) 203-1112
from the U.S. or (719) 457-0820 when calling internationally, using
confirmation code 1274601. About Sirna Therapeutics Sirna
Therapeutics is a clinical-stage biotechnology company developing
RNAi-based therapies for serious diseases and conditions, including
age-related macular degeneration (AMD), hepatitis B and C,
dermatology, asthma, Huntington's disease, diabetes and oncology.
Sirna Therapeutics completed its Phase 1 clinical trial for
Sirna-027 in AMD in 2005 and with its strategic partner, Allergan,
Inc., expects to move Sirna-027 into Phase 2 clinical trials in
2006. Sirna has selected a clinical compound for hepatitis C virus,
Sirna-034, which the Company plans to bring into Phase 1 clinical
trials by the end of 2006. Sirna has established an exclusive
multi-year strategic alliance with GlaxoSmithKline for the
development of siRNA compounds for the treatment of respiratory
diseases. Sirna has a leading intellectual property portfolio in
RNAi covering over 250 mammalian gene and viral targets and over
200 issued or pending patents covering other major aspects of RNAi
technology, including microRNA technology. More information on
Sirna Therapeutics is available on the Company's web site at
http://www.sirna.com/. Safe Harbor Statement Statements in this
press release which are not strictly historical are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. For example, most drug candidates
do not become approved drugs. The development of Sirna-027 and
Sirna-034 as well as Sirna's other programs are still at a
relatively early stage. All of these programs, and Sirna's ability
to obtain milestone and royalty payments for them, are subject to
significant risks and unknowns, are highly contingent upon future
successes, and require significant funding. In addition, patent
applications may not result in issued patents, and issued patents
may not be enforceable or could be invalidated. Other risks and
uncertainties include, among others, Sirna's early stage of
development and short operating history, Sirna's history and
expectation of losses and need to raise capital, Sirna's need to
obtain clinical validation and regulatory approval for Sirna-027,
Sirna-034 and Sirna's other product candidates, any of which could
have negative results, Sirna's need to engage collaborators,
Sirna's need to obtain and protect intellectual property, and the
risk of third-party patent infringement claims. These and
additional risk factors are identified in Sirna's Securities and
Exchange Commission filings, including Forms 10-K and 10-Q and in
other SEC filings. Sirna undertakes no obligation to revise or
update any forward- looking statements in order to reflect events
or circumstances that may arise after the date of this release.
Contacts: Stephan Herrera, Executive Director, Investor Relations,
Sirna Therapeutics, Inc., 415-512-7200 DATASOURCE: Sirna
Therapeutics, Inc. CONTACT: Stephan Herrera, Executive Director of
Investor Relations of Sirna Therapeutics, Inc., +1-415-512-7200 Web
site: http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Jul 2023 to Jul 2024